factors. We have risk classified each of these patients by a computer programme according to the WHO/ISH scheme. However, the blood pressure was only measured on one occasion (mean of two measures). Left ventricular hypertrophy was not recorded in this MONICA sample.
P-330 DIABETIC HYPERTENSIVE PATIENT -GUIDELINES FOR ACTION AND POSSIBLE DIFFICULTIES
Weimar K.S. Barroso, Paulo C.V. Jardim, Thiago S.V. Jardim, Claudio T.S. Souza, Alessandro L.A. Magalhaes, Priscila V.O. Couto, Estelamaris T. Monego. 1 Hypertension League, Federal University of Goias, Goiania, Goias, Brazil For hypertensive patients, the indication is to control BP in such a way as not to exceed Ͻ140/90mm Hg. In diabetic patients (DM) treatment goals are more rigorous (Ͻ130/85mm Hg), and it is recommended that ACE inhibitors be used as the first line of drugs. The authors evaluated BP control and other cardiovascular risk factors (CVRF) in diabetic patients, in a reference center For the treatment of Hypertension. Patients with Diabetes Mellitus (02 fasting glycemia curvesϾ126 mg/dl and/or those who were taking hypoglycemic drugs or insulin) were studied. They were evaluated in the first (M1) and last visit (M2), in terms of BP, Body Mass Index (BMI), hypotensive drugs being used, glycemia, cholesterol (CT), creatinine and potassium. There were 146 patients with a diagnosis of Diabetes. Mean age was 61.65 years (range 32 to 90 years), and there were 27 males (18.5%) among those recruited for this study. Mean follow up was 5.5 years. At M1, 10.4% of the patients were not taking any drugs, 50.6% were taking only one type of drug, 30.8% two, and 8.2% of the patients were taking three or more drugs. At M2, these figures changed to 10.9%, 39%, 39.7% and 10.4%, respectively. Diuretic drugs were the most prevalent (47.9% at M1 and 50.6% at M2). ACE inhibitors were used by 24.6% of the patients in the beginning and by 41.7% at the end. A significant decrease in BP (15.5/10.4mm Hg respectively, for SP and DP) was verified, but only 17.1% reached the BPϽ130x85 mm Hg goal, while only 41.7% were able to decrease BP levels to Ͻ140x90mm Hg. Other risk factors for cardiovascular diseases remained unchanged. The use of ACE inhibitors increased but not to desired levels. These data reinforce the need to use a more aggressive approach for these patients, despite social and economic limitations that could possibly interfere with treatment compliance. Taking into account all the risk factors and blood pressure levels as indicated by several American and European recommendations available since 1997, is a leading strategy to reduce mortality and morbidity of hypertensive patients. The aim of this study was to quantify how, in 1999, French practionners apply recommendations on hypertension (HTN), diabetes and hypercholesterolemia in recently diagnosed hypertensive patients and to evaluate whether or not the recommended targets are met. 1639 french GPs and cardiologists included 5831 recently diagnosed (7.5Ϯ3.6 months) hypertensives (57Ϯ12years of age, M/Fϭ55/45%). Initial BP was 173Ϯ15/99Ϯ9mmHg. 56% had no concomitant disease, 36% had either diabetes, dyslipidemia or coronary heart disease, 8% had at least two concomitant diseases. At the time of the study corresponding to 6.3Ϯ3.8months after initiation of diet and/or medical treatment, their BP was 148Ϯ17/86Ϯ11mmHg . At that time only 37% of patients with stage 2 HTN were encouraged to adopt lifestyle modifications without any medical treatment as recommended by the JNC VI. Among these hypertensives, measurement of plasma cholesterol was performed in only 61%, HDL-C/LDL-C in 26% and blood glucose in 51%. In the patients with dyslipidemia, LDL-C was measured in only 47%. In the 677 diabetic patients only 27% had a glycated hemoglobin measurement. The percentage of patients reaching target BP was 59% as regard DBPϽ90 mmHg, 25% as regard SBPϽ140mmHg, and 23% reached both target values of BP. In addition, 30% of patients with dyslipidemia reached the target LDL-C as defined by french recommendations (ANAES 1996) and 30% of the diabetic patients reached the target value for glycemia recommended by ADA (1997) .
In 1999 in France, a minority of patients reaches the national or international recommended target values for blood pressure, glycemia and plasma LDL-cholesterol. In spite of that, french practionners do not implement all the available diagnostic tools to improve the treatment of metabolic disorders in hypertensive patients.
As a conclusion, to improve the prognosis of hypertensive patients, it is mandatory to raise the awareness of physicians about multiple risk factor management and help them implement the recommendations in their daily practice.
